PrM- and cell-binding domains of the dengue virus E protein

Journal of Virology

Volumn 73, Issue 3, 1999, Pages 2547-2551

  Wang, Songli ^a   He, Runtao ^a,b   Anderson, Robert ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b NATIONAL EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS PROTEIN;

ANIMAL CELL; ARTICLE; DENGUE; DENGUE VIRUS; FLAVIVIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; VERO CELL; VIRUS ASSEMBLY; VIRUS CELL INTERACTION; VIRUS INFECTION; VIRUS PARTICLE;

EID: 0033053594     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.3.2547-2551.1999     Document Type: Article

References (29)

1. Allison, S. L., J. Schalich, K. Stiasny, C. W. Mandl, C. Kunz, and F. X. Heinz. 1995. Oligomeric rearrangement of tick-borne encephalitis virus envelope proteins induced by an acidic pH. J. Virol. 69:695-700.
2. Allison, S. L., K. Stadler, C. W. Mandl, C. Kunz, and F. X. Heinz. 1915. Synthesis and secretion of recomhinant tick-borne encephalitis virus protein E in soluble and particulate form. J. Virol. 69:5816-5820.
3. Anderson, R., A. D. King, and B. L. Innis. 1992. Correlation of E protein binding with cell susceptibility to dengue 4 virus infection. J. Gen. Virol. 73:2155-2159.
4. Anderson, R., S. Wang, C. Osiowy, and A. C. Issekutz. 1997. Activation of endothelial cells via antibody-enhanced dengue virus infection of peripheral blood monocytes. J. Virol. 71:4226-4232.
5. Chen, Y., T. Maguire, R. E. Hileman, J. R. Fromm, J. D. Esko, R. J. Linhardt, and R. M. Marks. 1997. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat. Med. 3:866-871.
6. Chen, Y., T. Maguire, and R. M. Marks. 1996. Demonstration of binding of dengue virus envelope protein to target cells. J. Virol. 70:8765-8772.
7. Daughaday, C. C., W. E. Brandt, J. M. McCown, and P. K. Russell. 1981. Evidence for two mechanisms of dengue virus infection of adherent human monocytes: trypsin-sensitive virus receptors and trypsin-resistant immune complex receptors. Infect. Immun. 32:469-473.
8. Fonseca, B. A. L., S. Pincus, R. E. Shope, E. Paoletti, and P. W. Mason. 1994. Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice. Vaccine 12:279-285.
9. Guirakhoo, F., R. A. Bolin, and J. T. Roehrig. 1992. The Murray Valley encephalitis virus prM protein confers acid resistance to virus particles and alters the expression of epitopes within the R2 domain of E glycoprotein. Virology 191:921-931.
10. He, R. T., B. L. Innis, A. Nisalak, W. Usawattanakul, S. Wang, S. Kalayanarooj, and R. Anderson. 1995. Antibodies that block virus attachment to Vero cells are a major component of the human neutralizing antibody response against dengue virus type 2. J. Med. Virol. 45:451-461.
11. Heinz, F. X., S. L. Allison, K. Stiasny, J. Schalich, H. Holzmann, C. W. Mandl, and C. Kunz. 1995. Recombinant and virion-derived soluble and particulate immunogens for vaccination against tick-borne encephalitis. Vaccine 13:1636-1642.
12. Heinz, F. X., C. W. Mandl, H. Holzmann, C. Kunz, B. A. Harris, F. Rey, and S. C. Harrison. 1991. The flavivirus envelope protein E: isolation of a soluble form from tick-borne encephalitis virus and its crystallization. J. Virol. 65: 5579-5583.
13. Heinz, F. X., K. Stiasny, G. Puschner-Auer, H. Holzmann, S. L. Allison, C. W. Mandl, and C. Kunz. 1994. Structural changes and functional control of the tick-borne encephalitis virus glycoprotein E by the heterodimeric association with protein prM. Virology 198:109-117.
14. Henchal, E. A., J. M. McCown, D. S. Burke, M. C. Seguin, and W. E. Brandt. 1985. Epitopic analysis of antigenic determinants on the surface of dengue 2 virions using monoclonal antibodies. Am. J. Trop. Med. Hyg. 34:162-169.
15. Hiramatsu, K., M. Tadano, R. Men, and C.-J. Lai. 1996. Mutational analysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence. Virology 224:437-445.
16. Hochstenbach, F., V. David, S. Watkins, and M. B. Brenner. 1992. Endoplasmic reticulum resident protein of 90 kilodaltons associates with the T-and B-cell antigen receptors and major histocompatibility complex antigens during their assembly. Proc. Natl. Acad. Sci. USA 89:4734-4738.
17. Kliks, S. C., A. Nisalak, W. E. Brandt, L. Wahl, and D. S. Burke. 1989. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 40:444-451.
18. Lobigs, M., R. Usha, A. Nestorowicz, I. D. Marshall, R. C. Weir, and L. Dalgarno. 1990. Host cell selection of Murray Valley encephalitis virus variants altered at an RGD sequence in the envelope protein and in mouse virulence. Virology 176:587-595.
19. Mackall, J., M. Meredith, and M. D. Lane. 1979. A mild procedure for the rapid release of cytoplasmic enzymes from cultured animal cells. Anal. Biochem. 95:270-274.
20. Mason, P. W., S. Pincus, M. J. Fournier, T. L. Mason, R. E. Shope, and E. Paoletti. 1991. Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection. Virology 180:294-305.
21. Megret, F., J. P. Hugnot, A. Falconar, M. K. Gentry, D. M. Morens, J. M. Murray, J. J. Schlesinger, P. J. Wright, P. Young, M. H. V. Van Regenmortel, and V. Deubel. 1992. Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein. Virology 187:480-491.
22. Pincus, S., P. W. Mason, E. Konishi, B. A. L. Fonseca, R. E. Shope, C. M. Rice, and E. Paoletti. 1992. Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis. Virology 187:290-297.
23. Putnak, R., D. A. Barvir, J. M. Burrous, D. R. Dubois, V. M. D'Andrea, C. H. Hake, J. C. Sadoff, and K. H. Eckels. 1996. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J. Infect. Dis. 174:1176-1184.
24. Randolph, V. B., G. Winkler, and V. Stollar. 1990. Acidotropic amines inhibit proteolytic processing of flavivirus prM protein. Virology 174:450-458.
25. Rey, F. A., F. X. Heinz, C. Mandl, C. Kunz, and S. C. Harrison. 1995. The envelope glycoprotein from tick-borne encephalitis virus at 2A resolution. Nature 375:291-298.
26. Rice, C. M. 1996. Flaviviridae: the viruses and their replication, p. 931-959. In B. N. Fields, D. M. Knipe, P. M. Howley, et al. (ed.), Fields virology. Lippincolt-Raven, Philadelphia, Pa.
27. Schalich, J., S. L. Allison, K. Stiasny, C. W. Mandl, C. Kunz, and F. X. Heinz. 1996. Recombinant subviral particles from tick-borne encephalitis virus are fusogenic and provide a model system for studying flavivirus envelope glycoprotein functions. J. Virol. 70:4549-4557.
28. Trirawatanapong, T., B. Chandran, R. Putnak, and R. Padmanabhan. 1992. Mapping of a region of dengue virus type-2 glycoprotein required for binding by a neutralizing monoclonal antibody. Gene 116:139-150.
29. Wang, S., R. He, J. Patarapotikul, B. L. Innis, and R. Anderson. 1995. Antibody-enhanced binding of dengue-2 virus to human platelets. Virology 213:254-257.